Follow the people · Insider
Steven Gannon
Steven Gannon files insider transactions with the SEC as a director of Xenon Pharmaceuticals (XENE). We hold 1 disclosed purchase or sale filed since 22 May 2015, 1 of them in the last 90 days.
- Files forXENE
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure13 August 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 21 May 2015 — 11 August 2026Director · Xenon Pharmaceuticals (XENE)28 Form 4 lines · source: SEC Form 4
- Filed 19 January 2020 — 4 June 2024Director · Fusion Pharmaceuticals (FUSN)16 Form 4 lines · source: SEC Form 4
Everything they disclosed
44 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 10,000 shares of Xenon PharmaceuticalsSEC Form 413 August 2026Common Shares · traded 11 August 2026 · filed 13 August 2026
- exercised options over 2,645 shares of Xenon PharmaceuticalsSEC Form 43 June 2026Common Shares · traded 1 June 2026 · filed 3 June 2026
- had shares withheld for tax on 1,416 shares of Xenon PharmaceuticalsSEC Form 43 June 2026Common Shares · traded 1 June 2026 · filed 3 June 2026
- exercised options over 2,645 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 43 June 2026Restricted Share Units · traded 1 June 2026 · filed 3 June 2026
- was granted 10,507 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 43 June 2026Share Option (Right to Buy) · traded 3 June 2026 · filed 3 June 2026
- was granted 1,593 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 43 June 2026Restricted Share Units · traded 3 June 2026 · filed 3 June 2026
- exercised options over 3,500 shares of Xenon PharmaceuticalsSEC Form 413 May 2026Common Shares · traded 12 May 2026 · filed 13 May 2026
- exercised options over 3,500 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 413 May 2026Stock Option (Right to Buy) · traded 12 May 2026 · filed 13 May 2026
- was granted 17,012 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 46 June 2025Share Option (Right to Buy) · traded 5 June 2025 · filed 6 June 2025
- was granted 2,645 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 46 June 2025Restricted Share Units · traded 5 June 2025 · filed 6 June 2025
- ▼ sold on the open market 3 shares of Xenon PharmaceuticalsSEC Form 46 June 2025Common Shares · traded 5 June 2025 · filed 6 June 2025
- exercised options over 5,144 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 416 May 2025Stock Option (Right to Buy) · traded 14 May 2025 · filed 16 May 2025
- exercised options over 5,144 shares of Xenon PharmaceuticalsSEC Form 416 May 2025Common Shares · traded 14 May 2025 · filed 16 May 2025
- was granted 15,542 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 45 June 2024Stock Option (Right to Buy) · traded 5 June 2024 · filed 5 June 2024
- returned to the issuer 141,011 shares of Fusion Pharmaceuticals (a derivative holding)SEC Form 44 June 2024Stock Option (Right to Buy) · traded 4 June 2024 · filed 4 June 2024
- returned to the issuer 30,000 shares of Fusion Pharmaceuticals (a derivative holding)SEC Form 44 June 2024Stock Option (Right to Buy) · traded 4 June 2024 · filed 4 June 2024
- returned to the issuer 17,000 shares of Fusion Pharmaceuticals (a derivative holding)SEC Form 44 June 2024Stock Option (Right to Buy) · traded 4 June 2024 · filed 4 June 2024
- returned to the issuer 17,000 shares of Fusion Pharmaceuticals (a derivative holding)SEC Form 44 June 2024Stock Option (Right to Buy) · traded 4 June 2024 · filed 4 June 2024
- returned to the issuer 17,000 shares of Fusion Pharmaceuticals (a derivative holding)SEC Form 44 June 2024Stock Option (Right to Buy) · traded 4 June 2024 · filed 4 June 2024
- returned to the issuer 56,400 shares of Fusion PharmaceuticalsSEC Form 44 June 2024Common Stock · traded 4 June 2024 · filed 4 June 2024
- ▼ sold on the open market 1,000 shares of Xenon PharmaceuticalsSEC Form 48 March 2024Common Shares · traded 7 March 2024 · filed 8 March 2024
- ▼ sold on the open market 5,000 shares of Xenon PharmaceuticalsSEC Form 48 March 2024Common Shares · traded 7 March 2024 · filed 8 March 2024
- ▼ sold on the open market 5,000 shares of Xenon PharmaceuticalsSEC Form 48 March 2024Common Shares · traded 7 March 2024 · filed 8 March 2024
- ▼ sold on the open market 2,000 shares of Xenon PharmaceuticalsSEC Form 48 March 2024Common Shares · traded 7 March 2024 · filed 8 March 2024
- was granted 17,000 shares of Fusion Pharmaceuticals (a derivative holding)SEC Form 414 June 2023Stock Option (Right to Buy) · traded 14 June 2023 · filed 14 June 2023
- was granted 18,475 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 42 June 2023Stock Option (Right to Buy) · traded 2 June 2023 · filed 2 June 2023
- ▲ bought on the open market 44,400 shares of Fusion PharmaceuticalsSEC Form 411 August 2022Common Stock · traded 11 August 2022 · filed 11 August 2022
- was granted 18,000 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 429 June 2022Stock Option (Right to Buy) · traded 28 June 2022 · filed 29 June 2022
- was granted 17,000 shares of Fusion Pharmaceuticals (a derivative holding)SEC Form 422 June 2022Stock Option (Right to Buy) · traded 14 June 2022 · filed 22 June 2022
- ▲ bought on the open market 2,829 shares of Fusion PharmaceuticalsSEC Form 423 August 2021Common Stock · traded 23 August 2021 · filed 23 August 2021
- ▲ bought on the open market 171 shares of Fusion PharmaceuticalsSEC Form 420 August 2021Common Stock · traded 18 August 2021 · filed 20 August 2021
- ▲ bought on the open market 3,000 shares of Fusion PharmaceuticalsSEC Form 420 August 2021Common Stock · traded 19 August 2021 · filed 20 August 2021
- ▲ bought on the open market 6,000 shares of Fusion PharmaceuticalsSEC Form 417 August 2021Common Stock · traded 16 August 2021 · filed 17 August 2021
- was granted 17,000 shares of Fusion Pharmaceuticals (a derivative holding)SEC Form 47 June 2021Stock Option (Right to Buy) · traded 4 June 2021 · filed 7 June 2021
- was granted 10,000 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 43 June 2021Stock Option (Right to Buy) · traded 3 June 2021 · filed 3 June 2021
- was granted 141,011 shares of Fusion Pharmaceuticals (a derivative holding)SEC Form 430 June 2020Stock Option (Right to Buy) · traded 19 January 2020 · filed 30 June 2020
- was granted 30,000 shares of Fusion Pharmaceuticals (a derivative holding)SEC Form 430 June 2020Stock Option (Right to Buy) · traded 25 June 2020 · filed 30 June 2020
- was granted 10,000 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 42 June 2020Stock Option (Right to Buy) · traded 1 June 2020 · filed 2 June 2020
- was granted 15,000 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 418 September 2019Stock Option (Right to Buy) · traded 16 September 2019 · filed 18 September 2019
- was granted 15,000 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 45 June 2018Stock Option (Right to Buy) · traded 4 June 2018 · filed 5 June 2018
- ▲ bought on the open market 15,000 shares of Xenon PharmaceuticalsSEC Form 414 August 2017Common Shares · traded 11 August 2017 · filed 14 August 2017
- was granted 3,500 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 42 June 2017Stock Option (Right to Buy) · traded 1 June 2017 · filed 2 June 2017
- was granted 3,500 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 43 June 2016Stock Option (Right to Buy) · traded 2 June 2016 · filed 3 June 2016
- was granted 5,144 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 422 May 2015Stock Option (Right to Buy) · traded 21 May 2015 · filed 22 May 2015
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.